https://www.selleckchem.com/products/agi-6780.html
Group C patients will be treated as per local practice and followed to assess overall survival. The study's platform design allows for adaptability to include emerging treatments related to novel resistance mechanisms. The primary endpoint is confirmed objective response rate (investigator assessed). Other endpoints are progression-free survival, duration of response, overall survival, pharmacokinetics and safety. ORCHARD aims to characterize mechanisms of resistance to first-line osimertinib and explore treatments to overcome acquired
Like
Comment
Share
